Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on April 12, 2019. The filing reports the immediate effectiveness of a corporate action regarding the company's capital structure. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a current report focused solely on a corporate governance event.
Material Changes
- Reverse Stock Split: The Company effected a one-for-twelve reverse split of its outstanding common stock.
- Effective Time: The split became effective at 7:00 a.m. Eastern Daylight Time on April 12, 2019.
- Share Reclassification: Each twelve shares of Common Stock issued and outstanding were reclassified and combined into one share of Common Stock.
- Corporate Filing: A Certificate of Amendment to the Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State to effectuate the split.
Guidance, Outlook, and Management Commentary
The filing does not provide financial guidance, future outlook, or management commentary regarding business operations. The primary communication is the announcement of the Reverse Stock Split and the appointment of Olde Monmouth Stock Transfer Co., Inc. as the exchange agent. Stockholders holding shares in "street name" will receive instructions from their banks or brokers, while record stockholders will receive a letter of transmittal.
Investor Verification Checklist
- Verify the adjusted share count and price per share following the one-for-twelve reverse split.
- Confirm receipt of the letter of transmittal or broker instructions for exchanging pre-split shares.
- Review the attached Certificate of Amendment (Exhibit 3.1) for any other changes to the Articles of Incorporation.
- Check subsequent filings for any impact on the company's compliance with Nasdaq or other exchange listing requirements.